Last reviewed · How we verify
Low-dose epinephrine
Low-dose epinephrine acts as a sympathomimetic agent that stimulates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and cardiac output.
Low-dose epinephrine acts as a sympathomimetic agent that stimulates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and cardiac output. Used for Septic shock and distributive shock (hemodynamic support), Cardiogenic shock (inotropic support), Anaphylaxis.
At a glance
| Generic name | Low-dose epinephrine |
|---|---|
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Drug class | Sympathomimetic amine / Catecholamine |
| Target | Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Critical Care |
| Phase | FDA-approved |
Mechanism of action
Epinephrine binds to alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors throughout the body. At low doses, beta-2 effects (vasodilation, bronchodilation) may predominate, while higher doses favor alpha-1 effects (vasoconstriction). Low-dose epinephrine is used clinically to support cardiovascular function and perfusion in critically ill patients.
Approved indications
- Septic shock and distributive shock (hemodynamic support)
- Cardiogenic shock (inotropic support)
- Anaphylaxis
Common side effects
- Tachycardia
- Hypertension
- Arrhythmias
- Anxiety and tremor
- Tissue necrosis at infusion site
Key clinical trials
- Effect of Adding a Low-Dose Epinephrine Bolus Prior to Infusion on Maternal Hemodynamic Stability During Cesarean Section (PHASE3)
- Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency (PHASE4)
- Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial (PHASE2)
- Twice Weekly Steroids and Exercise as Therapy for DMD (PHASE2)
- Impact of Low Dose Epinephrine in the Management of Out-of-hospital Cardiac Arrest on Neurological Outcome (PHASE3)
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (EARLY_PHASE1)
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PHASE3)
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-dose epinephrine CI brief — competitive landscape report
- Low-dose epinephrine updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI